AbbVie's eight-week Viekirax + Exviera program gets positive reviews
AbbVie, a global biopharmaceutical company, recently announced its Viekirax + Exviera eight-week treatment program has been granted a positive opinion by the European Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »